Skip to main content

Advertisement

SpringerLink
Log in

Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to evaluate the effects and the utility of second-line everolimus treatment for regrown renal angiomyolipoma (AML) with tuberous sclerosis complex (TSC) after transcatheter arterial embolization (TAE).

Methods

We investigated a total of 14 patients who underwent second-line everolimus treatment for TSC–AML that regrew after TAE, and assessed their effects and adverse events. Everolimus treatment was performed for AML with a maximum diameter of 4 cm. To determine the reduction ratio of AML, the volume of AML was measured using multislice helical computed tomography. Adverse events were evaluated according to CTCAE v4.0-JCOG. We further compared the treatment effect and adverse events with those in patients receiving first-line everolimus treatment.

Results

The AML volume decreased in all patients, with a ≥ 50% volume decrease in 57% (8 of 14) of the cases, and the mean reduction rate was 53%. We observed no significant difference in the mean reduction rate of AML between second-line everolimus treatment for regrown TSC–AML after TAE and first-line everolimus treatment for TSC–AML. The adverse events were mild and consistent with those reported in our previous study.

Conclusion

Although further studies are needed, everolimus appears to be effective as second-line treatment for TSC–AML that regrew after TAE and a beneficial treatment option for TSC–AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Osborne JP, Fryer A, Webb DW (1991) Epidemiology of tuberous sclerosis. Ann NY Acad Sci 615:125–127

    Article  CAS  Google Scholar 

  2. van Slegtenhorst M, de Hoogt R, Hermans C et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805–808

    Article  Google Scholar 

  3. The European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305–1315

    Article  Google Scholar 

  4. Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657–658

    Article  CAS  Google Scholar 

  5. Castagnetti M, Vezzu B, Laverda A et al (2007) Urological counseling and follow up in pediatric tuberous sclerosis complex. J Urol 178:2155–2159

    Article  Google Scholar 

  6. Kaneda MW, Tanaka M, Hamasaki T et al. (2013) Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS One 8:e63910

    Article  Google Scholar 

  7. Neumann HP, Schwarzkopf G, Henske EP (1998) Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Semin Pediatr Neurol 5:269–275

    Article  CAS  Google Scholar 

  8. Rouviere O, Nivet H, Grenier N et al. (2013) Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn Interv Imaging 94:225–237

    Article  CAS  Google Scholar 

  9. Hatano T, Chikaraishi K, Inaba Y et al. (2016) Outcomes of everolimus treatment for renal angiomyolipoma with tuberous sclerosis complex: a single institution experience in Japan. Int J Urol 23:833–838

    Article  CAS  Google Scholar 

  10. Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group (2013) Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediat Neurol 48:255–265

    Google Scholar 

  11. Ewalt DH, Diamond N, Rees C et al (2005) Long term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol 174:1764–1766

    Article  Google Scholar 

  12. Rakowski SK, Winterkorn EB, Paul E et al (2006) Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 70:1777–1782

    Article  CAS  Google Scholar 

  13. Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet 381:817–824

    Article  CAS  Google Scholar 

  14. Bissler JJ, Kingswood JC, Radzikowska E et al (2016) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized, controlled trial. Nephrol Dial Transplant 31:111–119

    Article  CAS  Google Scholar 

  15. Hatano T, Atsuta M, Inaba Y, Endo K, Egawa S (2018) Effect of everolimus treatment for renal angiomyolipoma with tuberous sclerosis complex: an evaluation based on tumor density. Int J Clin Oncol 23:547–552

    Article  CAS  Google Scholar 

  16. Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda T (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78–82

    Article  Google Scholar 

  17. Kumar S, Jayant K, Singh SK, Agrawal S (2015) A case series & review of literature of angiomyolipoma with medical & surgical perspective. J Clin Diagn Res 9:PD05–PD07

    PubMed  PubMed Central  Google Scholar 

  18. Sheth RA, Feldman AS, Paul E et al. (2016) Angiographic and volumetric effects of mammalian target of rapamycin inhibitors on angiomyolipoma in tuberous sclerosis. World J Radiol 8:308–315

    Article  Google Scholar 

  19. Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45:1015–1020

    Article  CAS  Google Scholar 

  20. Ha SH, Park JH, Jang HR et al (2014) Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function. BMC Cancer 14:906

    Article  Google Scholar 

  21. Hatano T, Inaba Y, Endo K, Egawa S (2017) Intermittent everolimus administration for renal angiomyolipoma with tuberous sclerosis complex. Int J Urol 24:780–785

    Article  CAS  Google Scholar 

  22. Krummel T, Garmon J, Lang H, Gangi A, Hannedouche T (2014) Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition. BMC Urol 14:77

    Article  Google Scholar 

  23. Park BK, Kim CK, Park SY, Shen S (2013) Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes. Acta Radiol 54:418–427

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, JR Tokyo General Hospital, 2-1-3 Yoyogi Shibuya-ku, Tokyo, 151-8528, Japan

    Takashi Hatano, Taishi Matsu-ura, Kei-ichiro Mori & Katsuhisa Endo

  2. Department of Urology, Jikei University School of Medicine, Tokyo, Japan

    Hiroyuki Inaba & Shin Egawa

  3. Research Center for Medical Science Core Research Facilities for Basic Science, Jikei University School of Medicine, Tokyo, Japan

    Mayumi Tamari

Authors
  1. Takashi Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taishi Matsu-ura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kei-ichiro Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katsuhisa Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mayumi Tamari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shin Egawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Hatano.

Ethics declarations

Conflict of interest

The authors of this article declare no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hatano, T., Matsu-ura, T., Mori, Ki. et al. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization. Int J Clin Oncol 23, 1134–1139 (2018). https://doi.org/10.1007/s10147-018-1325-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1325-0

Keywords

Search

Navigation